About the Iris Melanocytic Tumor Session
Iris melanocytic tumors are rare intraocular growths originating from melanocytes, the cells responsible for producing pigment. While often benign, some can progress to melanoma, a potentially deadly form of cancer. Research in this field aims to better understand the genetic and environmental factors influencing tumor development, as well as to improve diagnostic techniques for early detection. Advanced imaging technologies and genetic testing have enabled more accurate assessment of tumor characteristics, aiding in treatment decisions and prognostic evaluation. Additionally, targeted therapies are being explored to specifically inhibit pathways involved in tumor growth and spread. Continued investigation into iris melanocytic tumors holds promise for improved patient outcomes through personalized treatment approaches and enhanced surveillance strategies.
Topics Covered in Iris Melanocytic Tumor
Iris Nevus
Iris Melanoma
Anterior Segment Imaging
Growth Surveillance
Secondary Glaucoma
Iridectomy & Brachytherapy
Related Scientific Sessions at CIOC 2027
Why Attend the Iris Melanocytic Tumor Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Iris Melanocytic Tumor work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Iris Melanocytic Tumor research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Iris Melanocytic Tumor track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Iris Melanocytic Tumor Conference 2027 — FAQs
What is the Iris Melanocytic Tumor track at CIOC 2027?
The Iris Melanocytic Tumor track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Iris Melanocytic Tumor. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Iris Melanocytic Tumor sessions?
Cancer researchers and clinicians, educators and students with an interest in Iris Melanocytic Tumor are all welcome — whether presenting or attending.
Can I present my research in the Iris Melanocytic Tumor track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Iris Melanocytic Tumor sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Iris Melanocytic Tumor track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.